4.85 USD
-0.12 (-2.41%)
Overall SANA gets a fundamental rating of 2 out of 10. We evaluated SANA against 525 industry peers in the Biotechnology industry. SANA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SANA is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- In the past year SANA has reported negative net income.
- SANA had a negative operating cash flow in the past year.
- In the past 5 years SANA always reported negative net income.
- In the past 5 years SANA always reported negative operating cash flow.
1.2 Ratios
- SANA has a Return On Assets (-53.83%) which is comparable to the rest of the industry.
- With a Return On Equity value of -120.02%, SANA perfoms like the industry average, outperforming 40.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.83% | ||
| ROE | -120.02% | ||
| ROIC | N/A |
ROA(3y)-45.37%
ROA(5y)-41.34%
ROE(3y)-86.33%
ROE(5y)-74.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for SANA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The number of shares outstanding for SANA has been increased compared to 1 year ago.
- SANA has more shares outstanding than it did 5 years ago.
- SANA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of -3.58, we must say that SANA is in the distress zone and has some risk of bankruptcy.
- SANA has a Altman-Z score (-3.58) which is comparable to the rest of the industry.
- There is no outstanding debt for SANA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.58 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- SANA has a Current Ratio of 4.55. This indicates that SANA is financially healthy and has no problem in meeting its short term obligations.
- SANA's Current ratio of 4.55 is in line compared to the rest of the industry. SANA outperforms 52.38% of its industry peers.
- SANA has a Quick Ratio of 4.55. This indicates that SANA is financially healthy and has no problem in meeting its short term obligations.
- SANA has a Quick ratio (4.55) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.55 | ||
| Quick Ratio | 4.55 |
3. Growth
3.1 Past
- SANA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.91%, which is quite impressive.
EPS 1Y (TTM)41.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- SANA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.66% yearly.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y22.91%
EPS Next 2Y22.8%
EPS Next 3Y13.74%
EPS Next 5Y6.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- SANA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year SANA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- SANA's earnings are expected to grow with 13.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.8%
EPS Next 3Y13.74%
5. Dividend
5.1 Amount
- SANA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
SANA BIOTECHNOLOGY INC / SANA FAQ
Can you provide the ChartMill fundamental rating for SANA BIOTECHNOLOGY INC?
ChartMill assigns a fundamental rating of 2 / 10 to SANA.
What is the valuation status for SANA stock?
ChartMill assigns a valuation rating of 0 / 10 to SANA BIOTECHNOLOGY INC (SANA). This can be considered as Overvalued.
Can you provide the profitability details for SANA BIOTECHNOLOGY INC?
SANA BIOTECHNOLOGY INC (SANA) has a profitability rating of 1 / 10.